Please use this identifier to cite or link to this item: https://doi.org/10.1002/ajh.23213
DC FieldValue
dc.titleType II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group
dc.contributor.authorTse, E.
dc.contributor.authorGill, H.
dc.contributor.authorLoong, F.
dc.contributor.authorKim, S.J.
dc.contributor.authorNg, S.-B.
dc.contributor.authorTang, T.
dc.contributor.authorKo, Y.-H.
dc.contributor.authorChng, W.-J.
dc.contributor.authorLim, S.-T.
dc.contributor.authorKim, W.S.
dc.contributor.authorKwong, Y.-L.
dc.date.accessioned2016-07-08T07:19:42Z
dc.date.available2016-07-08T07:19:42Z
dc.date.issued2012-07
dc.identifier.citationTse, E., Gill, H., Loong, F., Kim, S.J., Ng, S.-B., Tang, T., Ko, Y.-H., Chng, W.-J., Lim, S.-T., Kim, W.S., Kwong, Y.-L. (2012-07). Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. American Journal of Hematology 87 (7) : 663-668. ScholarBank@NUS Repository. https://doi.org/10.1002/ajh.23213
dc.identifier.issn03618609
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/125295
dc.description.abstractEnteropathy-associated T-cell lymphoma (EATL) is a rare primary gastrointestinal T-cell lymphoma. A multicenter study from the Asia Lymphoma Study Group identified 38 EATL patients within a 19-year period. All cases were type II EATL. Men were affected twice as common as women, at a median age of 59 (23-89) years. None had a history of celiac disease. The sites of involvement were small bowel and stomach (5%), small bowel (63%), small and large bowel (16%), and large bowel (18%). Common presenting features were bowel perforation (34%), pain (32%), and obstruction (21%). Lymphomas showed monomorphic neoplastic lymphoid infiltrates that were CD3 + (100%), CD56 + (91%), TIA-1 + (96%), CD4 -CD8 + (63%), CD4 +CD8 + (19%), CD4 -CD8 - (16%), and CD4 +CD8 - (3%). Epstein Barr virus was demonstrable in three cases. Despite chemotherapy and/or surgical resection, the overall response and complete response rates were poor at 46% and 38%. The median overall survival (OS) was 7 months and progression-free-survival (PFS) 1 month. Five patients underwent hematopoietic stem cell transplantation all were alive. Age and the prognostic index for peripheral T-cell lymphoma were not prognostically significant. Good performance status was associated with better OS (P = 0.03), and response to initial treatment led to better OS and PFS (P < 0.001). © 2012 Wiley Periodicals, Inc.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1002/ajh.23213
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentPATHOLOGY
dc.contributor.departmentMEDICINE
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.description.doi10.1002/ajh.23213
dc.description.sourcetitleAmerican Journal of Hematology
dc.description.volume87
dc.description.issue7
dc.description.page663-668
dc.description.codenAJHED
dc.identifier.isiut000305209700004
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.